Scientists are opening a new front in the war on cancer with plans to develop "anti-evolution" drugs to stop tumour cells from developing resistance to treatment.
Britain's Institute of Cancer Research (ICR), one of the world's top cancer centres, said on Friday its initiative was the first to have at its heart the target of overcoming cancer evolution and drug resistance.
In the same way that bacteria evolve resistance to antibiotics, cancer cells also change to evade the medicines used to fight them, leading to "survival of the nastiest".
As a result, most cancer drugs eventually stop working, causing patients to relapse.
There are signs, however, that drugs can be developed to tackle this problem, while advances in immunotherapy may also make it possible to direct patients' immune systems to adapt in response to cancer changes.
News that makes sense
Your trusted source for staying up-to-date with the world around you. Get free daily news updates and analysis, straight to your inbox.
Over the next five years, the ICR aims to discover at least one new drug targeting a novel evolutionary mechanism and a new immunotherapy.
While doctors have known about cancer drug resistance for decades, it is only now, with advances in genetics and the development of ultra-fast DNA sequencing, that scientists are unravelling the factors driving the process.
"We now have an incredibly precise understanding of the genetic basis for resistance," said ICR Chief Executive Paul Workman.
Already an experimental medicine inhibiting the protein Hsp90, which cancer cells use to protect themselves from stress, has shown encouraging results in clinical trials. ICR scientists are also working on an even more important controller of the stress response known as HSF1.
The end result is likely be the development of a number of combination treatments to stop cancer evolving, similar to the drug cocktails used to control HIV or tuberculosis.
In addition to understanding biology, a large part of the research effort will be driven by "big data", through the use of mathematical models to predict the path of cancer evolution from tumour samples.
